SEARCH

SEARCH BY CITATION

References

  • 1
    Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, Siebert U. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-536.
  • 2
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 3
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 4
    McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, et al. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology 2010; 138: 922-931.
  • 5
    Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat 2009; 16: 644-649.
  • 6
    Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. HEPATOLOGY 2011; 54: 1547-1558.
  • 7
    Amin J, Law MG, Micallef J, Jauncey M, Van Beek I, Kaldor JM, Dore G.J. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect 2007; 135: 144-150.
  • 8
    O'shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. HEPATOLOGY 2010; 51: 307-328.
  • 9
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
  • 10
    Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003; 38: 864-870.
  • 11
    Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007; 36: 731-737.
  • 12
    Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. HEPATOLOGY 1998; 27: 1717-1722.
  • 13
    Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. HEPATOLOGY 1997; 26: 485-490.
  • 14
    Verbaan H, Widell A, Bondeson L, Andersson K, Eriksson S. Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence. J Viral Hepat 1998; 5: 43-51.
  • 15
    Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. HEPATOLOGY 1998; 28: 805-809.
  • 16
    Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, Zylberberg H, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998; 28: 945-950.
  • 17
    Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005; 3: 1150-1159.
  • 18
    The Scottish Health Survey 2008. Available at: http://www.scotland.gov.uk/Publications/2009/09/28102003/79. Accessed 1st May 2012.
  • 19
    Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004; 15: 543-549.
  • 20
    Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985; 122: 904-914.
  • 21
    Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998; 316: 989-991.
  • 22
    Efron B, Tibshirani R. An Introduction to the Bootstrap (Chapman & Hall/CRC Monographs on Statistics & Applied Probability). Boca Raton, FL: Chapman & Hall/CRC; 1993.
  • 23
    Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 1332-1338.
  • 24
    Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10: 1-113, iii.
  • 25
    Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-205, iii.
  • 26
    Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. HEPATOLOGY 2012; 55: 49-57.
  • 27
    Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15: i-xii, 1-210.
  • 28
    Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009; 25: 171-180.
  • 29
    National Institute of Clinical Excellence. Available at: http://www.nice.org.uk/nicemedia/live/13486/58478/58478.pdf. Accessed 1st March 2012.
  • 30
    National Institute of Clinical Excellence. Available at: http://www.nice.org.uk/nicemedia/live/13482/58368/58368.pdf. Accessed 1st March 2012.
  • 31
    Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol 2012; 24: 646-655.
  • 32
    Russell M, Patricia P, Moore CD, Chia C, Dorrell J, Cunanan R, et al. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan. HEPATOLOGY 2012 Apr 5. doi: 10.1002/hep.25755.
  • 33
    Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006; 59: 144-152
  • 34
    Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
  • 35
    Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-2191.
  • 36
    Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
  • 37
    Negro F. Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always. HEPATOLOGY 2002; 36: 1050-1052.
  • 38
    Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340: c912.
  • 39
    Centers for Disease Control. Hepatitis C Acute 2011 case definition. Available at: http://www.cdc.gov/osels/ph_surveillance/nndss/casedef/hepatitiscacutecurrent.htm. Accessed 1st March 2012.
  • 40
    Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331.
  • 41
    Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. HEPATOLOGY 2008; 48: 418-431.
  • 42
    Dore GJ, Freeman AJ, Law M, Kaldor JM. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings. Antivir Ther 2003; 8: 365-372.